Document is current
Any future updates will be listed below
-
Authors
Gonzales, Mitzi M. https://orcid.org/0000-0002-8467-0938
Garbarino, Valentina R. https://orcid.org/0000-0002-0973-7186
Kautz, Tiffany F.
Song, Xuemei
Lopez-Cruzan, Marisa https://orcid.org/0000-0003-0285-1012
Linehan, Leslie
Van Skike, Candice E. https://orcid.org/0000-0002-9258-7771
De Erausquin, Gabriel A. https://orcid.org/0000-0001-6423-4461
Galvan, Veronica https://orcid.org/0000-0002-4501-8568
Orr, Miranda E. https://orcid.org/0000-0002-0418-2724
Musi, Nicolas
He, Yingxin https://orcid.org/0000-0003-2543-4553
Bateman, Randall J. https://orcid.org/0000-0002-7729-1702
Wang, Chen-Pin
Seshadri, Sudha
Kraig, Ellen
Kellogg, Dean Jr
- License Information
-
More Information
Article History
Received: 4 October 2024
Accepted: 8 May 2025
First Online: 20 May 2025
Competing interests
: Mitzi M. Gonzales reports personal stock in AbbVie. Miranda Orr has a patent, Biosignature and Therapeutic Approach for Neuronal Senescence, pending. Randall J. Bateman reports a relationship with C2N Diagnostics and receives income from serving on the scientific advisory board as a co-founder. Randall J. Bateman has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb, and Novartis. Washington University has equity ownership interest in C2N Diagnostics and receives royalty income based on technology (Stable Isotope Labeling Kinetics, Blood Plasma Assay, and Methods of Diagnosing AD with Phosphorylation Changes) licensed by Washington University to C2N Diagnostics. Dr. Seshadri has consulted for Eisai and Biogen outside the current work. All other authors declare no competing interests.
